After years of clinical research, your company submits a New Drug Application for a drug evaluated in children with Attention Deficit Hyperactivity Disorder (ADHD). You are surprised to receive a complete response letter from the FDA. They note that your trials failed to demonstrate significant efficacy in signs of hyperactivity, although efficacy for symptoms of inattention were statistically significant. What is the best option based on this information